NCT01669408

Brief Summary

Elevated body temperature was shown to be associated with worse outcome in acute stroke patients. PreCOOL 1 aims to investigate efficacy, feasibility and safety of prehospital cooling with cold infusions in stroke patients.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for phase_2 stroke

Timeline
Completed

Started Sep 2012

Shorter than P25 for phase_2 stroke

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 14, 2012

Completed
7 days until next milestone

First Posted

Study publicly available on registry

August 21, 2012

Completed
11 days until next milestone

Study Start

First participant enrolled

September 1, 2012

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2013

Completed
Last Updated

June 24, 2013

Status Verified

June 1, 2013

Enrollment Period

1 year

First QC Date

August 14, 2012

Last Update Submit

June 21, 2013

Conditions

Keywords

ischemic strokehemorrhagic strokeprehospital coolinginduction of coolingambulanceemergency roomcold infusionshypothermianormothermia

Outcome Measures

Primary Outcomes (1)

  • Tympanic Temperature

    Primary endpoint: Change of tympanic temperature between measurements before prehospital start of cooling an at arrival in the emergency room.

    from randomization (prehospital) until arrival in the ER, an expected average of 45min

Secondary Outcomes (4)

  • Efficacy

    single measurement at arrival in the ER

  • Vital parameters

    from randomization (prehospital) until arrival in the ER, an expected average of 45min

  • Tolerability

    from randomization (prehospital) until arrival in the ER, an expected average of 45min

  • Safety

    from randomization (prehospital) until first neuroimaging (ER), an expected average of 80min

Study Arms (2)

Cold infusions

ACTIVE COMPARATOR

Infusion of 1L cold crystalloid solution (4°C) over 15 minutes

Drug: Cold crystalloid infusions, 0.9%NaCl or Ringer's solution

Control group

NO INTERVENTION

Best medical treatment following international stroke guidelines

Interventions

Infusion of 1L cold crystalloid solution (4°C) over 15 minutes

Cold infusions

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Suspected stroke
  • Symptom onset ≤ 7 days
  • Tympanic temperature ≥ 36.7°C
  • Informed consent by the patient
  • Age ≥ 18 years

You may not qualify if:

  • Severe cardiac insufficiency (NYHA ≥ III)
  • New anisocoria, severe nausea, vomiting or headache
  • High-grade heart valve stenosis or insufficiency
  • Acute pulmonary embolism
  • Acute myocardial infarction
  • Threatening ventricular dysrhythmia
  • Known hematologic disease with increased risk of thrombosis (e.g. cryoglobulinemia, cold agglutinins, sickle cell anemia)
  • Known vasospastic vascular disorder (e.g. Raynaud's phenomenon or thromboangiitis obliterans)
  • Severe renal insufficiency with reduced diuresis
  • Pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Rescue service, Dept. of Anesthesiology, University Hospital Heidelberg

Heidelberg, 69120, Germany

RECRUITING

MeSH Terms

Conditions

StrokeIschemic StrokeHemorrhagic StrokeEmergenciesHypothermia

Interventions

Sodium ChlorideRinger's Solution

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular DiseasesDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsBody Temperature ChangesSigns and Symptoms

Intervention Hierarchy (Ancestors)

ChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium CompoundsIsotonic SolutionsSolutionsPharmaceutical Preparations

Study Officials

  • Sven Poli, Dr. med.

    University Hospital Heidelberg

    PRINCIPAL INVESTIGATOR
  • Erik Popp, PD Dr. med.

    University Hospital Heidelberg

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr. Sven Poli, Consultant Neurologist, Principical Investigator

Study Record Dates

First Submitted

August 14, 2012

First Posted

August 21, 2012

Study Start

September 1, 2012

Primary Completion

September 1, 2013

Study Completion

September 1, 2013

Last Updated

June 24, 2013

Record last verified: 2013-06

Locations